LLY vs. JNJ, MRK, ABBV, NVO, AZN, NVS, ABT, UNH, TMO, and PFE
Should you be buying Eli Lilly and Company stock or one of its competitors? The main competitors of Eli Lilly and Company include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), AbbVie (ABBV), Novo Nordisk A/S (NVO), AstraZeneca (AZN), Novartis (NVS), Abbott Laboratories (ABT), UnitedHealth Group (UNH), Thermo Fisher Scientific (TMO), and Pfizer (PFE). These companies are all part of the "medical" sector.
Johnson & Johnson (NYSE:JNJ) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, community ranking, valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership and risk.
In the previous week, Johnson & Johnson had 1 more articles in the media than Eli Lilly and Company. MarketBeat recorded 34 mentions for Johnson & Johnson and 33 mentions for Eli Lilly and Company. Eli Lilly and Company's average media sentiment score of 0.87 beat Johnson & Johnson's score of 0.60 indicating that Johnson & Johnson is being referred to more favorably in the media.
69.6% of Johnson & Johnson shares are held by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are held by institutional investors. 0.2% of Johnson & Johnson shares are held by company insiders. Comparatively, 0.1% of Eli Lilly and Company shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Johnson & Johnson currently has a consensus target price of $175.86, suggesting a potential upside of 20.16%. Eli Lilly and Company has a consensus target price of $728.05, suggesting a potential downside of 0.92%. Given Eli Lilly and Company's higher probable upside, equities research analysts clearly believe Johnson & Johnson is more favorable than Eli Lilly and Company.
Johnson & Johnson has higher revenue and earnings than Eli Lilly and Company. Johnson & Johnson is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Johnson & Johnson has a net margin of 45.26% compared to Johnson & Johnson's net margin of 15.36%. Johnson & Johnson's return on equity of 51.22% beat Eli Lilly and Company's return on equity.
Johnson & Johnson pays an annual dividend of $4.76 per share and has a dividend yield of 3.2%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.7%. Johnson & Johnson pays out 29.7% of its earnings in the form of a dividend. Eli Lilly and Company pays out 89.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Johnson & Johnson has raised its dividend for 63 consecutive years and Eli Lilly and Company has raised its dividend for 10 consecutive years. Johnson & Johnson is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
Eli Lilly and Company received 86 more outperform votes than Johnson & Johnson when rated by MarketBeat users. Likewise, 69.98% of users gave Eli Lilly and Company an outperform vote while only 64.91% of users gave Johnson & Johnson an outperform vote.
Johnson & Johnson has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.34, suggesting that its stock price is 66% less volatile than the S&P 500.
Summary
Johnson & Johnson beats Eli Lilly and Company on 13 of the 21 factors compared between the two stocks.
Get Eli Lilly and Company News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LLY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eli Lilly and Company Competitors List
Related Companies and Tools
